VOI
16.3.2020 08:02:10 CET | Business Wire | Press release
Micromobility. Moving Cities into a Sustainable Future finds that Voi has reduced emissions by 71% over a year on e-scooters used in Paris by introducing best-practice measures and a new scooter model with a swappable battery.
- Voi’s Paris scooters now produce 35g CO2 equivalents per person per kilometre, on par with many public transport options
- Swappable battery scooters and cargo bike operations helped achieve a 51% reduction in emissions
- Voiager 3 - the latest Voi model with a swappable battery - is expected to have a 24 month lifespan
- The average emission level of new cars in the EU is 120.4g CO2/km
The report also finds that:
- E-scooters are being taken up at 4 x the rate of e-bikes
- There are over 20 million users of e-scooters across Europe
- E-scooters have accumulated over 300 million trips globally in two years
- Since launched in California in September 2017, e-scooters have reached 626 cities across 53 countries
- 63% of Voi’s users have combined e-scooters with public transport
Please see below a statement from Voi’s co-founder and CEO Fredrik Hjelm to go with the EY report and a link to the report Micromobility. Moving Cities into a Sustainable Future here .
“Fundamental to Voi’s mission has been our belief that e-scooters and micro mobility can transform the way that people live, work and move through cities. We are delighted to see that EY also recognises the huge benefits that e-scooters could bring to cities and their potential to transform mobility options. In particular we are proud that our efforts to reduce emissions from our Paris operations have demonstrated that e-scooters can be just as sustainable an option as public transport, and produce a fraction of the emissions of new cars. Using insight from real-world data and interviews with city officials, this report shows how e-scooters are making the biggest impact, and where work still needs to be done.”
“We're under no illusion that e-scooters are the silver bullet when it comes to sustainable cities. Nevertheless the improvements we have made to our fleet and the supply chain are already shifting the dial. We very much welcome the report’s conclusion that e-scooters offer unprecedented potential but only when there are clear regulations that foster responsible and sustainable behaviour."
John Simlett, EY’s Global Future of Mobility Leader, says:
“Micromobility is here to stay, reducing emissions as well as relieving pressure on public transport systems, but cities and providers need to work together to seize this opportunity.
“In order to ensure that it takes its rightful place in the urban mobility ecosystem of tomorrow, the next phase of development in micromobility needs to be handled in a more collaborative, integrated and responsible way. This will require clear regulations on responsible and sustainable use, and increasing public access to micromobility infrastructure.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
